ChemComm
Communication
Table 1 ED50 (CD concentration giving 50% K+ efflux, mM) and LC50 (CD
concentration giving 50% bacterial cell viability, mM) for CDs 3, 6, and 8–10a
derivative with excessive hydrophobicity, such as 4 with naphthyl
groups, did not disrupt the bacterial membrane, while CD 6 with a
cyclohexyl group and slightly lower hydrophobicity permeabilized
both bacterial and red blood cell membranes. Reducing the size of
the hydrophobic ring to phenyl, cyclopentyl, and cyclobutyl groups
led to retention of antibiotic activity with a dramatic decrease in
toxicity against red blood cell membranes, while further reduction in
size to a cyclopropyl ring led to no membrane activity. Thus, a
balance between hydrophobicity and hydrophilicity (or cationic
properties) may be important for expressing bioactivity.
E. coli
S. aureus
(Native)
(EDTA treated)
ED50/mM LC50/mM ED50/mM LC50/mM ED50/mM LC50/mM
3
6
8
9
20
20
450
50
50
450
450
100
450
50
50
450
450
—
50
20
10
50
450
10
50
20
10
50
450
—
5–10
5–10
20
5–10
5–10
20
450
5–10
10
450
GSb 5–10
In conclusion, CD derivatives possessing arylamino and alkyl-
a
Cells were incubated with a CD and peptide for 30 min at 37 1C. amino groups were prepared as novel membrane-disrupting
Gramicidin S, see ref. 12.
b
agents. The functionalization was accomplished via a versatile
release of inner ions in seconds.4 At the concentrations corre-
sponding to the MICs against S. aureus, the K+ efflux was only
20–30%, and therefore more than 60% of the bacteria were alive
when treated with CDs for 30 min under the experimental conditions
used in this study.
MW-assisted Huisgen reaction. Their bioactivity for the permeabi-
lization of bacterial and animal membranes depended on the
substituents on the amino group, leading to the possibility for
selective toxicity against bacteria. It is noteworthy that CD deriva-
tives possessing one kind of simple substituents exhibited activity
similar to that of peptides composed of a variety of amino acids.
The results presented herein demonstrate that our chemistry to
develop novel antimicrobial agents by use of CDs is promising.
Further studies are currently underway.
Next, the hemolysis of rabbit red blood cells by CDs 3, 6, and 8–10
was examined to determine whether they disrupt the membranes of
animal cells (Fig. 3). Focusing on the benzylamino group, compound
3 exhibited significantly less hemolysis at the experimental concen-
tration (B50 mM), while 1,7 with benzylamino groups bonded
directly to the C6 carbons, measurably permeabilized the red blood
cells (90% hemolysis at 50 mM), even though the MICs for the two
compounds were nearly the same. In addition, Fahmi et al.
described that the CD derivative for which the triazole group of 3
was replaced with an amido group exhibited reduced antimicrobial
activity.12 The triazole group, therefore, works very well not only for
versatile click functionalization but also for selective membrane
disruption. The cyclohexylmethylamino group of 6, however, per-
meabilized both bacterial and animal cell membranes. Notably,
removal of one of the methylene groups (cyclopentyl substituent in
compound 8) dramatically decreased the hemolytic activity. Its
activity below 20 mM was less than 10%, although its MIC against
S. aureus was 8 mg cmÀ3 (3 mM). Furthermore, the antimicrobial
cyclobutyl derivative 9 showed almost no hemolytic activity in the
dose range, while the cyclopropyl derivative 10 did not disrupt the
membrane. It is interesting that the membrane permeabilization
activity of the CD derivatives depends on their substituents. A CD
This work was supported by a Grant-in-Aid for Scientific
Research (KAKENHI 25460036) from the Japan Society for the
Promotion of Science.
Notes and references
1 (a) J. Li, R. L. Nation, R. W. Milne, J. D. Turnidge and K. Coulthard,
Int. J. Antimicrob. Agents, 2005, 25, 11; (b) A. P. Zavascki, L. Z. Goldani
and R. L. Nation, J. Antimicrob. Chemother., 2007, 60, 1206;
(c) M. Zasloff, Nature, 2002, 415, 389; (d) R. E. W. Hancock and
H. G. Sahl, Nat. Biotechnol., 2006, 24, 155.
2 M. R. Yeaman and N. Y. Yount, Pharmacol. Rev., 2003, 55, 27.
3 (a) K. Yamada, M. Unno, K. Kobayashi, H. Oku, H. Yamamura, S. Araki,
H. Matsumoto and R. Katakai, J. Am. Chem. Soc., 2002, 124, 12684;
(b) M. Kawai, R. Tanaka, H. Yamamura, K. Yasuda, S. Narita,
H. Umemoto, S. Ando and T. Katsu, Chem. Commun., 2003, 1264.
4 W. C. Wimley, ACS Chem. Biol., 2010, 5, 905–917 and references therein.
5 For example, see M. V. Rekharsky, H. Yamamura, M. Kawai and Y. Inoue,
J. Am. Chem. Soc., 2001, 123, 5360; H. Yamamura, M. V. Rekharsky,
Y. Ishihara, M. Kawai and Y. Inoue, J. Am. Chem. Soc., 2004, 126, 14224.
6 (a) H. Urakawa, K. Yamada, K. Komagoe, S. Ando, H. Oku, T. Katsu and
I. Matsuo, Bioorg. Med. Chem. Lett., 2010, 20, 1771; (b) V. V. Kapoerchan,
A. D. Knijnenburg, M. Niamat, E. Spalburg, A. J. de Neeling,
P. H. Nibbering, R. H. Mars-Groenendijk, D. Noort, J. M. Otero,
A. L. Llamas-Saiz, M. J. van Raaj, G. A. van der Marel, H. S. Overkleeft
and M. Overhand, Chem.–Eur. J., 2010, 16, 12174; (c) E. J. Prenner,
M. Kiricsi, M. Jelokhani-Niaraki, R. N. A. H. Lewis, R. S. Hodges and
R. N. McElhaney, J. Biol. Chem., 2005, 280, 2002.
7 H. Yamamura, K. Suzuki, K. Uchibori, A. Miyagawa, M. Kawai,
C. Omizo and T. Katsu, Chem. Commun., 2011, 48, 892.
8 H. Yamamura, K. Shimohara, R. Kurata, Y. Fujita, K. Murata,
T. Hayashi and A. Miyagawa, Chem. Lett., 2013, 6, 643.
9 (a) S. Srinivasachari, K. M. Fichter and T. M. Reineke, J. Am. Chem. Soc.,
´
´
´
2008, 130, 4618; (b) A. Mendez-Ardoy, M. Gomez-Garcıa, C. O. Mellet,
´
´
´
N. Sevillano, M. D. Giron, R. Salto, F. Santoyo-Gonzalez and
J. M. G. Fernandez, Org. Biomol. Chem., 2009, 7, 2657; (c) A. Martı,
´
´
´
´
C. Bienvieu, J. J. Blanco, P. Vierling, C. O. Mellet, J. M. Garcıa-Fernandez
and C. D. Giorgio, J. Org. Chem., 2013, 78, 8143.
10 T. Katsu, H. Kobayashi and Y. Fujita, Biochim. Biophys. Acta, 1986,
860, 608–619; T. Katsu, H. Nakagawa and K. Yasuda, Antimicrob.
Agents Chemother., 2002, 46, 1073.
11 C. Ohmizo and T. Katsu, J. Microbiol. Methods, 2004, 59, 173.
12 N. Fahmi, F. W. Schmidtman and S. Hecht, PP Pat., WO2006/
083678, 2006.
Fig. 3 Dose-dependence curves for hemolysis induced by the CD derivatives.
Rabbit erythrocytes were incubated with a CD derivative at 37 1C for 30 min,
and hemolysis was estimated by measuring the absorbance at 540 nm.
Lysolecithin (50 mM) was used to determine the 100% level of hemolysis.
5446 | Chem. Commun., 2014, 50, 5444--5446
This journal is ©The Royal Society of Chemistry 2014